Study of Surufatinib Combined With Sintilimab and SCRT in Advanced Solid Tumors
Status:
Not yet recruiting
Trial end date:
2025-09-30
Target enrollment:
Participant gender:
Summary
An exploratory clinical study of short course radiotherapy combined with surufatinib and
sintilimab in the treatment of relapsed and refractory advanced solid tumors